Drug Trial Radar · NCT00817635
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
Last checked: Nov 19, 2026Latest source record: Jun 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
155
Actual
Start
Dec 22, 2008
Primary completion
Oct 13, 2009
Study completion Oct 13, 2009
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- Great Lakes Drug Development, Inc.; Integrium
- First posted
- Jan 6, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
Conditions
- Hypertension
Interventions
LCI699Drug
LCI699 oral capsules
EplerenoneDrug
Eplerenone oral capsules
LCI699-matching PlaceboDrug
LCI699-matching placebo oral capsules
Eplerenone-matching PlaceboDrug
Eplerenone-matching placebo oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF)Time frame: Baseline, Week 8
Locations
38 sites in 2 countries. Site status is shown where the registry gives one.
Horizon Research Group, Inc
Mobile, Alabama
Cochise Clinical Research
Sierra Vista, Arizona
Clinical Solutions Advantage
Buena Park, California
Michael Waldman, MD
Irvine, California
Long Beach Center for Clinical Research
Long Beach, California
Clinical Trials Research
Roseville, California
Orange County Research Center
Tustin, California
Metro Clinical Research
Littleton, Colorado
Meridien Research
Bradenton, Florida
Clinical Research of So. Florida
Coral Gables, Florida
Jacksonville Heart Center
Jacksonville Beach, Florida
FPA Clinical Research
Kissimmee, Florida
Accelovance
Melbourne, Florida
Cardio-Pulminary Associates
Plantation, Florida
Meridien Research
St. Petersburg, Florida
Northwest Clinical Trials
Boise, Idaho
Provident Clinical Research
Addison, Illinois
Cedar-Crosse Research Centereet
Chicago, Illinois
Provident Clinical Research
Bloomington, Indiana
Accelovance
South Bend, Indiana
Peter A. Holt
Baltimore, Maryland
MD Medical Research
Oxon Hill, Maryland
Chelsea Internal Medicine
Chelsea, Michigan
New York Cardiovascular Associates
New York, New York
Charlotte Clinical Research
Charlotte, North Carolina
Northstate Clinical Research
Lenoir, North Carolina
Community Research
Cincinnati, Ohio
Tipton Medical & Diagnostic Center
Tipton, Pennsylvania
Medical Research South
Charleston, South Carolina
Mountain View Clinical Research Associates
Greer, South Carolina
Clinical Research Associates, Inc
Nashville, Tennessee
Punzi Medical Center
Carrollton, Texas
KRK Medical Research
Dallas, Texas
DCOL Center for Clinical Research
Longview, Texas
Daniel Gottlieb, MD
Burien, Washington
Rainier Clinical Research Center
Renton, Washington
Gemini Scientific
Madison, Wisconsin
Encode Clinic
Reykjavik, SA, Iceland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.